Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.66 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | FBP1 | P09467 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | CLK1 | P49759 | 1/20 | 0.59 |
| ▸ | TEK | Q02763 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169874 | 1.00 | EGFR (0.68) | EGFRERBB2KDREPHB4EPHA2 | |
| SCHEMBL12743526 | 1.00 | EGFR (0.68) | EGFRERBB2KDREPHB4EPHA2 | |
| SCHEMBL208809 | 1.00 | EGFR (0.68) | EGFRERBB2KDREPHB4EPHA2 | |
| SCHEMBL380402 | 0.97 | EGFR (0.70) | EGFRERBB2KDREPHB4EPHA2 | |
| SCHEMBL233105 | 0.94 | EGFR (0.74) | EGFRERBB2KDREPHB4EPHA2 | |
| SCHEMBL227365 | 0.94 | EGFR (0.74) | EGFRERBB2KDREPHB4EPHA2 | |
| SCHEMBL29623522 | 0.94 | EGFR (0.74) | EGFRERBB2KDREPHB4EPHA2 | |
| SCHEMBL208731 | 0.93 | EGFR (0.66) | EGFRERBB2KDREPHB4EPHA2 | |
| SCHEMBL208730 | 0.93 | EGFR (0.66) | EGFRERBB2KDREPHB4EPHA2 | |
| Methane SCHEMBL17035685 | 0.93 | EGFR (0.73) | EGFRERBB2KDREPHB4EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |